Browse Studies — Arctuva

Phase 1

A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations

To learn if the drug combination of adagrasib, cetuximab, and cemiplimab can help to control metastatic CRC with KRAS G12C mutations.

Metastatic Colorectal CancerKRAS G12C Mutations

Estimated

~$10 – $6,250

M.D. Anderson Cancer CenterNCT06412198

Phase 1

A Phase 1/1b, Open-label, Multicenter, Dose Escalation and Dose Optimization Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of KQB365 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies With KRAS G12S or G12C Mutations

The goal of this clinical trial is to learn if KQB365 works to treat advanced solid tumor cancer in adults. It will also learn about the safety of KQB365. The …

KRAS G12C MutationKRAS G12S MutationSolid Tumor Malignancies+1 more

Estimated

~$10 – $8,750

Kumquat Biosciences Inc.NCT06720987

Phase 1

An Open-Label, Phase 1/2 Dose Escalation, Dose Expansion and Cohort Expansion Study Evaluating the Safety, PK and Clinical Activity of FMC-376 in Participants With KRAS G12C Mutated Locally Advanced Unresectable or Metastatic Solid Tumors

The goal of this clinical trial is to evaluate FMC-376 in participants with advanced solid tumors with KRAS G12C mutations. This clinical trial will be conduct…

Advanced Solid Tumors With KRAS G12C MutationsSolid Tumor, AdultUnresectable Solid Tumor+5 more

Estimated

~$10 – $8,750

Frontier Medicines CorporationNCT06244771

Phase 1

Phase I/II Study of Ladarixin and Sotorasib in Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer (NSCLC)

This is a phase I/II, open-label, study of twice-daily oral ladarixin with sotorasib in participants with advanced KRASG12C mutant non-small cell lung cancer (…

Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation

Estimated

~$10 – $7,500

NYU Langone HealthNCT05815173